Work

Baseline fasting insulin is associated with early height gain during recombinant human growth hormone therapy in children with idiopathic short stature

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Fasting insulin modulates growth hormone (GH) signaling and insulin-like growth factor 1 (IGF-1) synthesis, but its relation to early height response to recombinant human GH (rhGH) therapy is unclear. We examined this in children with idiopathic short stature (ISS). Methods This single-center retrospective cohort study reviewed records of children aged 3–14 years who started rhGH monotherapy for ISS at a tertiary pediatric endocrinology center between December 2018 and December 2024. Children with another identifiable cause of short stature, obesity, diabetes, uncontrolled hypothyroidism, Turner syndrome or concurrent gonadotropin-releasing hormone agonist therapy were excluded. The primary outcome was the change in height standard deviation score (SDS) from baseline to 3 months, and the secondary outcomes were the 3-month height gain and the change in height SDS from baseline to 6 months. Baseline fasting insulin and the homeostatic model assessment of insulin resistance (HOMA-IR) were related to the outcomes by Spearman correlation and by linear regression adjusted for age, sex, baseline height SDS and baseline IGF-1 SDS, with a sensitivity model adding rhGH dose and Bonferroni correction. Results Of 224 eligible children, 169 with complete baseline and 3-month data formed the primary analysis set, and 210 with 6-month data were analyzed for the 6-month outcome. Baseline fasting insulin correlated with the 3-month change in height SDS [Spearman correlation coefficient (rs) = 0.667], the 3-month height gain (rs = 0.331) and the 6-month change in height SDS (rs = 0.500), all p < 0.0001 and significant after Bonferroni correction. In multivariable regression (coefficient of determination R 2 = 0.209), each 1 μ U/mL higher fasting insulin was associated with a 0.034 greater 3-month change in height SDS (95% confidence interval [CI] 0.018–0.050, p < 0.0001), and the association persisted after adjustment for rhGH dose (0.036, 95% CI 0.020–0.052). Conclusions Baseline fasting insulin was associated with early height SDS gain during rhGH therapy in children with ISS after adjustment for age, sex, baseline height SDS and IGF-1 SDS, although residual confounding, particularly by pubertal status, cannot be excluded. These retrospective, unvalidated findings are hypothesis-generating and do not support using fasting insulin to guide rhGH dosing.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234161828
FWCI:
Cites: 27
Cited by:
Related to: 10
Parts: 1